dc.contributor.author |
Ker, James A.
|
|
dc.date.accessioned |
2016-09-02T08:00:19Z |
|
dc.date.available |
2016-09-02T08:00:19Z |
|
dc.date.issued |
2016-08 |
|
dc.description.abstract |
Our concept of ST-segment Elevated Myocardial Infarction (STEMI) refers to when coronary blood supply decreases abruptly after a thrombotic occlusion. The underlying mechanism leading to the thrombotic event is an unstable atherosclerotic plaque which ruptured (or cracked or eroded) exposing the content of the plaque to the blood initiating thrombogenesis. |
en_ZA |
dc.description.department |
Internal Medicine |
en_ZA |
dc.description.librarian |
am2016 |
en_ZA |
dc.description.uri |
http://www.specialistforum.co.za |
en_ZA |
dc.identifier.citation |
Ker, J 2016, 'Pharmaceutical drugs in the treatment of STEMI', The Specialist Forum, vol. 16, no. 7, pp. 20. |
en_ZA |
dc.identifier.issn |
2218-8282 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/56589 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
New Media Publishing |
en_ZA |
dc.rights |
© The Specialist Forum |
en_ZA |
dc.subject |
Thrombotic occlusion |
en_ZA |
dc.subject |
Unstable atherosclerotic plaque |
en_ZA |
dc.subject |
Coronary blood supply |
en_ZA |
dc.subject |
ST-segment Elevated Myocardial Infarction (STEMI) |
en_ZA |
dc.title |
Pharmaceutical drugs in the treatment of STEMI |
en_ZA |
dc.type |
Article |
en_ZA |